Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 169 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tuberculosis, Mycobacterium Infection Clear all

Conditions: Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions: Delamanid, Optimized Background Regimen (OBR), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: TB Multi-drug Resistant
Interventions: SQ109, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Latent Tuberculosis
Interventions: TB Infection ECHO; Other
Lead sponsor: Kent Hospital, Rhode Island; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pawtucket, Rhode Island

Conditions: Latent Tuberculosis
Interventions: Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tuberculosis, HIV Infections
Interventions: Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6); Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 21
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 17 more

Conditions: Tuberculosis
Interventions: Rifapentine, 25-desacetyl Rifapentine, Isoniazid; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more

Conditions: Tuberculosis
Interventions: Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyridoxine hydrochloride, Levofloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 7 more

Conditions: Tuberculosis
Interventions: Multivitamins, Placebo; Dietary Supplement · Other
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tuberculosis
Interventions: CST001; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Tuberculosis
Interventions: CST001; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multi-drug Resistant Tuberculosis
Interventions: Pretomanid; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections, Tuberculosis
Interventions: Cycloserine, Ethionamide, Capreomycin sulfate, Aminosalicylic acid, Streptomycin sulfate, Ethambutol hydrochloride, Amikacin sulfate, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin, Clofazimine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 21
States / cities: Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more

Conditions: Advanced Cancer
Interventions: T-SPOT TB test; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Tuberculosis
Interventions: Ethambutol; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Tuberculosis, Pulmonary
Interventions: Azacitidine Injection; Drug
Lead sponsor: Andrew Dinardo; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tuberculosis
Interventions: BCG Vaccine USP, Isoniazid, Rifampin; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: Rifampin & midazolam, rifapentine and midazolam; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tuberculosis Infection
Interventions: Aplisol@ PPD material, Reference Standard; Biological
Lead sponsor: JHP Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Tuberculosis
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 65 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Groton, Connecticut • Bethesda, Maryland

Conditions: Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions: BCG TICE Vaccine; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Latent Tuberculosis, HIV Infections
Interventions: T-Spot.TB test; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Tuberculosis
Interventions: BCG TICE strain; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Decatur, Georgia • St Louis, Missouri

Search by objective public record fields.

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Dose Escalation Study of SQ109 in Healthy Adult Volunteers

Improving Rhode Island's Tuberculosis Preventive Services in Primary Care

Economic Incentives and vDOT for Latent Tuberculosis Infection

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

Tuberculosis Research Blood Bank

A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin

Nutrition, Immunology and Epidemiology of Tuberculosis

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Evaluation of the QuantiFERON-TB Test.

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Latent Tuberculosis Infection in Cancer Patients

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

Azacytidine During Anti-tuberculosis Therapy

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

Equivalence Study of Specificity of PPD

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?

A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

Challenge Model for Assessment of Human TB Immunity